Posted by Michael Wonder on 30 Jan 2017
Cancer drugs price rise 'costing NHS millions'
29 January 2017 - UK prices for generic cancer drugs have risen sharply in the past five years, restricting their use in treating NHS patients, research from the European Cancer Congress has found.
Drugs such as tamoxifen and busulphan are now 10 times more expensive despite no longer being under patent.
The British Generic Manufacturers Association said trusts often paid much less than the list price.
The Department for Health said it has plans to cut generic drug costs.
